Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- MSD Seeks Japan Nod for RSV Antibody Clesrovimab
July 15, 2025
- Takeda’s OX2R Agonist Makes Mark in PIII NT1 Trials, US Filing Planned in FY2025
July 15, 2025
- FDA Rejects Capricor/Nippon Shinyaku’s DMD Cell Therapy, Seeking More Data
July 15, 2025
- Eisai Launches Gout Drug Urece in China
July 15, 2025
- Japan’s Feliqs to Relocate Headquarters to US, Launch PIb for ROP Drug
July 15, 2025
- JWP-Led Holdings Firm Launched for Nichi-Iko, Kyowa, and Teva Takeda
July 15, 2025
- Merck Japan Joins Hands with Kawasaki City Incubator to Support Startups
July 15, 2025
- Taking on Solid Tumors - 8: Amgen Gains Early Lead with TCE Imdelltra, More Assets in the Pipeline
July 14, 2025
- MSD Files for Japan Approval of Once-Daily HIV Combo Pill
July 14, 2025
- Toho, Teijin, and Itochu to Jointly Build Regenerative Medicine Ecosystem
July 14, 2025
- Solasia Invests in Sweden’s Isofol as Colorectal Cancer Trials Resume
July 14, 2025
- All Three PPI Switch OTCs Approved following MHLW Panel OK
July 14, 2025
- More Firms Signal Interest in Meiji-Daito Consortium to Revamp Generic Production
July 14, 2025
- Espha President Signals Move Toward Novel Drug Development amid Group Shift
July 11, 2025
- Izervay US Sales Reach 15.9 Billion Yen in April-June: Astellas
July 11, 2025
- Taiho’s DMD Drug TAS-205 Falls Short in PIII Trial
July 9, 2025
- JCR Licenses Gene Therapy Platform to Alexion
July 9, 2025
- Japan’s CAR-T Market Set to Double by 2030, Hitting 39 Billion Yen: Fuji Keizai
July 9, 2025
- Japan Ethical Drug Sales Up 0.5% in May: Crecon
July 9, 2025
- ASKA Targets 30% Overseas Sales Ratio through Southeast Asia Expansion: New President
July 9, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…